Neoadjuvant Chemo Flops Versus Upfront Surgery for Resectable Pancreatic Cancer
(MedPage Today) -- CHICAGO -- Neoadjuvant chemotherapy failed to match upfront surgery for survival in resectable pancreatic cancer, a small randomized trial showed.
Unexpectedly, patients assigned to surgery first lived more than a year longer...
Source: MedPage Today Surgery - Category: Surgery Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Surgery